Sialix Inc. has changed its name to Siamab Therapeutics.Siamab Therapeutics is a biopharmaceutical company developing therapies targeting abnormal carbohydrates found only on cancer cells. These tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors, and are exploited by tumor cells to hijack glycan-dependent biological processes to their advantage, thus ensuring tumor growth and dissemination. Therefore, therapeutic antibodies targeting TACAs have the potential to not only kill cancer cells but also inhibit critical biological functions in cancer progression.
Siamab Therapeutics has developed a platform of technologies that enable the discovery and development of highly specific, high affinity, anti-TACA therapeutic antibodies. Siamab's core technologies were licensed from the laboratory of Dr. Ajit Varki (UCSD), a world expert in glycobiology and sialic-acid biochemistry. Siamab has brought together a world-leading team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support our anti-TACA antibody discovery and development programs.
Current Team (6)Update
Funding Rounds (4) - $6.2MUpdate
Board Members and Advisors (16)Update
Bring innovative ideas into the clinic
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of...
Desert Angels is an angel investor group focused on funding entrepreneurial ventures and startup...
Beacon Angels is a Boston-based angel group that makes investments in the $100,000 to $300,000...
Maine Angels was founded in 2003 to enhance regional economic development by providing a...
Sialix Scientific Headquarters
3210 Merryfield Row
San Diego, CA 92121
48 Wilde Road
Newton, MA 02468